CUE
Cue Biopharma, Inc.Company Information
- Company Name
- Cue Biopharma, Inc.
- CIK
- CIK0001645460
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CUE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CUE
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-30
- Last sale
- 2026-08-13
- Shares purchased (TTM)
- 323,857
- Shares sold (TTM)
- 32,715
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,641,349
- Shares outstanding
- 6,340,844
- Ownership
- 25.89%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -19.77%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 17 | 16 | 27 | 12 | 27 | 13 | 22 | 32 | 30 | 41 | 49 | 55 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | 7 | - | - | - | - | - | - | 0 | 0 | ||||||
| Accounts Receivable Net Current | 5 | 5 | 6 | 0 | 1 | 0 | 1 | 3 | 2 | 1 | 2 | 2 | ||||||
| Deposits Assets Current | 0 | 1 | 1 | 2 | 0 | 1 | 1 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | ||||||
| Value Added Tax Receivable Current | 2 | 2 | 2 | 2 | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 27 | 26 | 37 | 26 | 31 | 16 | 25 | 37 | 34 | 45 | 51 | 58 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 4 | 5 | 5 | 4 | 4 | 4 | 5 | 6 | 6 | 7 | ||||||
| Deposits Assets Noncurrent | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Value Added Tax Receivable Noncurrent | - | - | - | - | 2 | - | - | - | - | - | - | - | ||||||
| Assets | 31 | 31 | 42 | 32 | 41 | 22 | 32 | 45 | 42 | 54 | 62 | 69 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 4 | 2 | 4 | 4 | 3 | 6 | 4 | 4 | 4 | 2 | ||||||
| Accrued Liabilities Current | 15 | 1 | 2 | 2 | 2 | 4 | 3 | 3 | 5 | 5 | 4 | 5 | ||||||
| Other Loans Payable | - | - | - | - | - | 1 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | ||||||
| Other Long Term Debt Current | - | - | 0 | 1 | 2 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Other Loans Payable Current | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 21 | 7 | 13 | 16 | 19 | 15 | 14 | 17 | 16 | 18 | 17 | 17 | ||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 2 | 3 | 3 | 0 | 1 | 1 | 2 | 3 | 3 | 4 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | - | 0 | 1 | 2 | 3 | 4 | 5 | ||||||
| Other Loans Payable Long Term | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Liabilities | 28 | 9 | 16 | 18 | 23 | 16 | 15 | 19 | 21 | 24 | 24 | 26 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 529 | 395 | 395 | 383 | 381 | 361 | 359 | 358 | 345 | 344 | 338 | 330 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | 0 | - | - | - | - | - | - | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -527 | -374 | -368 | -370 | -363 | -354 | -342 | -332 | -324 | -314 | -301 | -288 | ||||||
| Stockholders Equity | 2 | 22 | 26 | 13 | 18 | 7 | 17 | 25 | 22 | 30 | 37 | 43 | ||||||
| Liabilities And Stockholders Equity | 31 | 31 | 42 | 32 | 41 | 22 | 32 | 45 | 42 | 54 | 62 | 69 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 200 | 200 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 5 | 3 | 3 | 3 | 3 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 5 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCue Biopharma, Inc. (CUE) — SEC Financial Statements & Analysis
Cue Biopharma, Inc. (CUE) is a pharmaceutical preparations company, incorporated in DE. Cue Biopharma, Inc. trades on Nasdaq as: CUE. Cue Biopharma, Inc. (CUE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Cue Biopharma, Inc. carries a market cap of $200.12M, a P/E ratio of -1.22x, a P/B ratio of 86.63x, a P/S ratio of 5.31x, an enterprise value of $182.73M, and an EV/EBITDA multiple of -1.88x. On profitability, it posts an operating margin of -262.03%, a net margin of -435.83%, a Return on Equity (ROE) of -1603.48%, and a Return on Assets (ROA) of -459.60%. Per share, it reports EPS of $-25.88, diluted EPS of $-25.88, free cash flow per share of $-7.91, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 354.37% year-over-year, net income growth of 321.93% year-over-year, and EPS growth of 111.73% year-over-year. On the balance sheet, it maintains a current ratio of 1.25x, a quick ratio of 1.16x, working capital of $5.41M, a debt-to-equity ratio of 12.29x, a debt ratio of 0.92, an interest coverage ratio of -127.31x, free cash flow of $-50.17M (TTM), and net debt of $-17.39M. Figures sourced from SEC EDGAR.
- Market Cap
- $200.12M
- P/E TTM
- -1.22x
- EPS TTM
- $-25.88
- P/B TTM
- 86.63x
- ROE TTM
- -1603.48%
- ROA TTM
- -459.60%
- Debt To Equity
- 12.29x
- Free Cash Flow TTM
- $-50.17M
- Net Revenue TTM Growth 1Y
- 354.37%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cue Biopharma, Inc. in?
Cue Biopharma, Inc. (CUE) operates in the Pharmaceutical Preparations industry.
What exchange does CUE trade on?
Cue Biopharma, Inc. (CUE) trades on the Nasdaq.
Where is Cue Biopharma, Inc. incorporated?
Cue Biopharma, Inc. is incorporated in DE.
When was Cue Biopharma, Inc. (CUE)'s most recent SEC filing?
Cue Biopharma, Inc. (CUE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is CUE's market cap?
Cue Biopharma, Inc. (CUE) has a market capitalization of $200.12M as of 2026-06-30.
What is CUE's EPS (earnings per share)?
Cue Biopharma, Inc. (CUE)'s trailing twelve month EPS is $-25.88 as of 2026-06-30.
What is CUE's ROE (return on equity)?
Cue Biopharma, Inc. (CUE)'s trailing twelve month Return on Equity (ROE) is -1603.48% as of 2026-06-30.
What is CUE's ROA (return on assets)?
Cue Biopharma, Inc. (CUE)'s trailing twelve month Return on Assets (ROA) is -459.60% as of 2026-06-30.
What is CUE's EV/EBITDA?
Cue Biopharma, Inc. (CUE)'s trailing twelve month EV/EBITDA is -1.88x as of 2026-06-30.